Aurinia Pharmaceuticals Inc Ordinary Shares Earnings Dividend

Aurinia Pharmaceuticals Inc Ordinary Shares’s revenue jumped 24.4% since last year same period to $77.71Mn in the Q1 2026. On a quarterly growth basis, Aurinia Pharmaceuticals Inc Ordinary Shares has generated 0.77% jump in its revenue since last 3-months.

Aurinia Pharmaceuticals Inc Ordinary Shares’s net profit jumped 47.17% since last year same period to $34.35Mn in the Q1 2026. On a quarterly growth basis, Aurinia Pharmaceuticals Inc Ordinary Shares has generated -83.7% fall in its net profits since last 3-months.

Aurinia Pharmaceuticals Inc Ordinary Shares’s net profit margin jumped 18.3% since last year same period to 44.21% in the Q1 2026. On a quarterly growth basis, Aurinia Pharmaceuticals Inc Ordinary Shares has generated -83.83% fall in its net profit margins since last 3-months.

Aurinia Pharmaceuticals Inc Ordinary Shares’s price-to-earnings ratio after this Q1 2026 earnings stands at 7.39.

Aurinia Pharmaceuticals Inc Ordinary Shares’s earning per share (EPS) estimates for the current quarter stand at 0.25 - a 56.25% jump from last quarter’s estimates.

Aurinia Pharmaceuticals Inc Ordinary Shares’s earning per share (EPS) estimates for the current year stand at 0.25.

Aurinia Pharmaceuticals Inc Ordinary Shares’s earning per share (EPS) jumped 56.25% since last year same period to 0.25 in the Q1 2026. This indicates that the Aurinia Pharmaceuticals Inc Ordinary Shares has generated 56.25% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Aurinia Pharmaceuticals Inc Ordinary Shares’s return on assets (ROA) stands at 0.14.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Aurinia Pharmaceuticals Inc Ordinary Shares’s return on equity (ROE) stands at 0.65.